1型脊髓灰质炎病毒感染患者中2型中和抗体的短暂出现。
Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.
作者信息
SABIN A B
出版信息
J Exp Med. 1952 Jul;96(1):99-106. doi: 10.1084/jem.96.1.99.
Abstract
Neutralizing antibodies for Type 2 (Lansing) poliomyelitis virus were tested periodically in a group of 18 patients from whom Type 1 poliomyelitis virus was recovered. Data for homotypic neutralizing antibodies and Type 2 complement-fixing antibodies were also available on the majority of these patients. The results indicated that Type 2 neutralizing antibodies first appeared or significantly increased in titer in 11 of the 18 patients during the first 2 to 4 weeks after onset. In most patients the Type 2 neutralizing antibody either completely disappeared at 3 months (in one patient between 2 and 4 weeks) or dropped in titer, while the Type 1 or homotypic antibody persisted in high titer. These results are interpreted as indicating that the Type 1 and Type 2 poliomyelitis viruses share a common antigen, and that the heterotypic anti-body response is transitory while the homotypic neutralizing antibody persists for a longer time.
摘要
对一组18例曾分离出1型脊髓灰质炎病毒的患者定期检测2型（兰辛株）脊髓灰质炎病毒中和抗体。大多数患者也有同型中和抗体及2型补体结合抗体的数据。结果表明，18例患者中有11例在发病后的头2至4周内首次出现2型中和抗体或其滴度显著升高。在大多数患者中，2型中和抗体在3个月时（1例在2至4周之间）完全消失或滴度下降，而1型或同型抗体则持续保持高滴度。这些结果被解释为表明1型和2型脊髓灰质炎病毒具有共同抗原，异型抗体反应是短暂的，而同型中和抗体持续时间更长。
相似文献
1
Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.1型脊髓灰质炎病毒感染患者中2型中和抗体的短暂出现。
J Exp Med. 1952 Jul;96(1):99-106. doi: 10.1084/jem.96.1.99.
2
Quantitative studies of the virus-host relationship in chimpanzees after inapparent infection with Coxsackie viruses. I. The virus carrier state and the development of neutralizing antibodies.柯萨奇病毒隐性感染后黑猩猩病毒-宿主关系的定量研究。I. 病毒携带状态及中和抗体的产生
J Exp Med. 1953 Mar;97(3):367-400. doi: 10.1084/jem.97.3.367.
3
Levels of homotypic neutralizing antibody in human poliomyelitis three years after infection.感染三年后人类脊髓灰质炎中同型中和抗体水平。
J Exp Med. 1952 Nov;96(5):477-90. doi: 10.1084/jem.96.5.477.
4
Homotypic complement-fixing antibody in monkeys infected with type 2 poliomyelitis virus by the oral route.经口感染2型脊髓灰质炎病毒的猴子体内的同型补体结合抗体。
J Exp Med. 1952 Jul;96(1):55-8. doi: 10.1084/jem.96.1.55.
5
Complement-fixing antibodies to type 2 (Lansing) poliomyelitis virus in a normal population of a subtropical area.亚热带地区正常人群中针对2型（兰辛型）脊髓灰质炎病毒的补体结合抗体
J Exp Med. 1952 Aug;96(2):175-85. doi: 10.1084/jem.96.2.175.
6
A specific complement-fixation test for infection with poliomyelitis virus.一种用于检测脊髓灰质炎病毒感染的特异性补体结合试验。
J Exp Med. 1951 Aug;94(2):123-37. doi: 10.1084/jem.94.2.123.
7
Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.人体中2型脊髓灰质炎补体结合抗体的产生、持续存在及其意义。
J Exp Med. 1952 Jul;96(1):35-53. doi: 10.1084/jem.96.1.35.
8
Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract.脊髓灰质炎患者对从其自身消化道分离出的病毒的抗体反应。
J Exp Med. 1949 Oct;90(4):349-72. doi: 10.1084/jem.90.4.349.
9
Ohio strains of a virus pathogenic for infant mice, Coxsackie group; simultaneous occurrence with poliomyelitis virus in patients with summer grippe.对幼鼠致病的一种病毒的俄亥俄毒株，柯萨奇病毒组；在夏季流感患者中与脊髓灰质炎病毒同时出现。
J Exp Med. 1950 Feb;91(2):185-95. doi: 10.1084/jem.91.2.185.
10
Modification of the homotypic specificity of poliomyelitis complement-fixing antigens by heat.加热对脊髓灰质炎补体结合抗原同型特异性的改变。
J Exp Med. 1956 Jul 1;104(1):99-120. doi: 10.1084/jem.104.1.99.
引用本文的文献
1
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.在健康成年人中使用或不使用大肠杆菌双突变不耐热肠毒素（dmLT）佐剂的灭活脊髓灰质炎病毒疫苗的安全性、耐受性和免疫原性：一项 1 期随机研究。
Vaccine. 2023 Mar 3;41(10):1657-1667. doi: 10.1016/j.vaccine.2023.01.048. Epub 2023 Feb 4.
2
Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.灭活脊髓灰质炎疫苗对黏膜免疫的影响：对脊髓灰质炎根除收官阶段的启示
Expert Rev Vaccines. 2015;14(8):1113-23. doi: 10.1586/14760584.2015.1052800. Epub 2015 Jul 9.
3
Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.2010年刚果共和国脊髓灰质炎致死性流行中一株1型脊髓灰质炎病毒对血清中和作用的抗性
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12889-94. doi: 10.1073/pnas.1323502111. Epub 2014 Aug 18.
4
Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.人体中2型脊髓灰质炎补体结合抗体的产生、持续存在及其意义。
J Exp Med. 1952 Jul;96(1):35-53. doi: 10.1084/jem.96.1.35.
5
Poliomyelitis Lansing antibodies in three population groups in Israel.以色列三个群体中的兰辛型脊髓灰质炎抗体
Bull World Health Organ. 1955;12(4):677-85.
6
Prevalence of poliomyelitis neutralizing antibodies in Norwegian school children before vaccination.挪威学童接种疫苗前脊髓灰质炎中和抗体的流行情况。
Arch Gesamte Virusforsch. 1959;9:348-59. doi: 10.1007/BF01248827.
7
A survey of poliovirus neutralizing antibody in Newfoundland, 1959-60.1959 - 1960年对纽芬兰脊髓灰质炎病毒中和抗体的调查。
Can Med Assoc J. 1961 Jul 8;85(2):63-7.
8
The development of homologous neutralizing antibody during a type 1 poliomyelitis epidemic.1型脊髓灰质炎流行期间同源中和抗体的产生
J Hyg (Lond). 1958 Sep;56(3):347-54. doi: 10.1017/s0022172400037839.
9
Poliovirus precipitins; a study by means of diffusion in agar.脊髓灰质炎病毒沉淀素；琼脂扩散法研究
J Exp Med. 1957 Nov 1;106(5):661-76. doi: 10.1084/jem.106.5.661.
10
The immune status of a population at the termination of a severe epidemic of poliomyelitis.小儿麻痹症严重流行结束时人群的免疫状况。
J Hyg (Lond). 1957 Jun;55(2):239-53. doi: 10.1017/s002217240003713x.
本文引用的文献
1
Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract.脊髓灰质炎患者对从其自身消化道分离出的病毒的抗体反应。
J Exp Med. 1949 Oct;90(4):349-72. doi: 10.1084/jem.90.4.349.
2
Serum neutralizing antibodies to the infecting strain of virus in poliomyelitis patients.脊髓灰质炎患者针对感染病毒株的血清中和抗体。
Proc Soc Exp Biol Med. 1948 Nov;69(2):256-8. doi: 10.3181/00379727-69-16682.
3
Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man.人体中2型脊髓灰质炎补体结合抗体的产生、持续存在及其意义。
J Exp Med. 1952 Jul;96(1):35-53. doi: 10.1084/jem.96.1.35.
4
Complement fixation with Brunhilde and Lansing poliomyelitis viruses propagated in tissue culture.用在组织培养中繁殖的布伦希尔德株和兰辛株脊髓灰质炎病毒进行补体结合试验。
Proc Soc Exp Biol Med. 1952 Feb;79(2):296-300. doi: 10.3181/00379727-79-19357.
5
Preparation of specific complement-fixing antigens from the three prototypes of poliomyelitis viruses.
Proc Soc Exp Biol Med. 1952 Jan;79(1):48-50. doi: 10.3181/00379727-79-19268.
6
Complement-fixation test for the Lansing strain of poliomyelitis virus.脊髓灰质炎病毒兰辛株的补体结合试验
Am J Hyg. 1951 Nov;54(3):391-401. doi: 10.1093/oxfordjournals.aje.a119494.
7
A specific complement-fixation test for infection with poliomyelitis virus.一种用于检测脊髓灰质炎病毒感染的特异性补体结合试验。
J Exp Med. 1951 Aug;94(2):123-37. doi: 10.1084/jem.94.2.123.
8
Poliomyelitis in Canadian Eskimos, laboratory studies. II.加拿大爱斯基摩人中的脊髓灰质炎，实验室研究。II.
Can J Med Sci. 1951 Aug;29(4):216-35. doi: 10.1139/cjms51-027.
9
Age incidence and seasonal development of neutralizing antibodies to lansing poliomyelitis virus.兰辛脊髓灰质炎病毒中和抗体的年龄发病率及季节性变化
Am J Hyg. 1950 Nov;52(3):323-47. doi: 10.1093/oxfordjournals.aje.a119427.
Zotero 插件